MODULE PHARMACOKINETICS WRITTEN SUMMARY
|
|
- Chester Horton
- 5 years ago
- Views:
Transcription
1 MODULE PHARMACOKINETICS WRITTEN SUMMARY
2 m Pharmacokinetics Written Summary 2013N179518_00 TABLE OF CONTENTS PAGE 1. BRIEF SUMMARY METHODS OF ANALYSIS ABSORPTION DISTRIBUTION Dolutegravir: In Vitro Distribution Studies Inhibition of BSEP, OAT1, OAT3, MATE1, MATE2-K and MRP4-mediated transport METABOLISM EXCRETION PHARMACOKINETIC DRUG INTERACTIONS Dolutegravir: In Vitro Studies Mechanism based pharmacokinetic evaluation to predict the effect of dolutegravir on tenofovir kidney exposure OTHER PHARMACOKINETIC STUDIES DISCUSSION AND CONCLUSIONS TO PHARMACOKINETICS STUDIES REFERENCES
3 m Pharmacokinetics Written Summary 2013N179518_00 LIST OF TABLES PAGE Table 4.1 List of New Distribution Studies Performed with Dolutegravir...8 Table 7.1 List of New Pharmacokinetic Drug Interaction Studies Performed with Dolutegravir
4 m Pharmacokinetics Written Summary 2013N179518_00 1. BRIEF SUMMARY Since the submission of the original New Drug Application for dolutegravir (NDA ), 2 new pharmacokinetic studies have been completed. In one study, dolutegravir interactions with additional transporters were investigated in vitro, and in the other study, dolutegravir interactions with tenofovir was predicted using a physiological based pharmacokinetic model. No new previously unsubmitted pharmacokinetic studies have been conducted with abacavir or lamivudine. Dolutegravir: Summary of New Findings Absorption Distribution In vitro, dolutegravir did not inhibit human bile salt export pump (BSEP), but did inhibit multidrug resistance-associated protein 4 (MRP4), organic cation transporter 1 and 3 (OAT1 and OAT3) and multidrug and toxin extrusion transporter1 and 2-K (MATE1 and MATE2-K). Metabolism Excretion Drug interactions Following multiple once daily or twice daily dosing of 50 mg DTG, no significant change in the renal clearance or proximal tubule concentration of tenofovir was predicted in a physiological based pharmacokinetic (PBPK) mechanistic kidney model. Other PK studies 4
5 m Pharmacokinetics Written Summary 2013N179518_00 2. METHODS OF ANALYSIS 5
6 m Pharmacokinetics Written Summary 2013N179518_00 3. ABSORPTION 6
7 m Pharmacokinetics Written Summary 2013N179518_00 4. DISTRIBUTION The new distribution study with dolutegravir is listed in Table Dolutegravir: In Vitro Distribution Studies Inhibition of BSEP, OAT1, OAT3, MATE1, MATE2-K and MRP4-mediated transport An in vitro study was designed to evaluate the ability of dolutegravir to act as an inhibitor of the renal transporters, organic anion transporter 1 and 3 (OAT1, OAT3), multidrug and toxin extrusion transporters 1 and 2-K (MATE1, MATE2-K), and multidrug resistance protein 4 (MRP4), and the hepatic cannilicular transporter, bile salt export pump (BSEP) by measuring the transporter-mediated activity in the presence or absence of dolutegravir at concentrations of 0.1, 1, 3, 10, 30 and 100 M with an additional concentration of 120 M for MRP4 [Report 2013N161621]. A tabulated summary of this study is presented in m2.6.5, Table 8.1. Dolutegravir did not inhibit the BSEP-mediated uptake of [ 3 H]taurocholic acid (TCA) by membrane vesicles expressing human BSEP. The MRP4-mediated transport of [ 3 H]estradiol 17 -D-glucuronide (E2G) into membrane vesicles expressing human MRP4 was inhibited by dolutegravir with an IC 50 value of 84.4 ± 3.0 M. Dolutegravir inhibited the OAT1-mediated uptake of [ 3 H]para aminohippuric acid (PAH) and the OAT3-mediated transport of [ 3 H]estrone sulfate (ES) in S 2 cells expressing human OAT1 or OAT3 with respective IC 50 values of 2.12 M (OAT1) and 1.97 M (OAT3). Dolutegravir inhibited the MATE1-mediated and the MATE2-K-mediated uptake of [ 14 C]metformin in HEK293 cells transfected with a vector containing human MATE1 or MATE2-K cdna, with respective IC 50 values of 6.34 M (MATE1) and 24.8 M (MATE2-K). 7
8 m Pharmacokinetics Written Summary 2013N179518_00 Table 4.1 List of New Distribution Studies Performed with Dolutegravir Type of Study Species (Strain)/ Test System No./Sex/ Group Method of Administration Form Dose (mg/kg/day) or Concentration Duration of Dosing (Sampling Occasions) GLP Testing Facility Report No. (Study No.) Location in CTD Inhibition of BSEP, OAT1, OAT3, MATE1, MATE2-K and MRP4 transport Human NA In vitro A 0.1 to 100 or 120 M NA No 2013N (XS-0406) m Key: A = GSK A, the sodium salt form. BSEP = Bile salt export pump. MATE = Multidrug and toxin extrusion. MRP = Multidrug resistance associated protein. NA = Not applicable. OAT = Organic anion transporter. Testing Facility: = 8
9 m Pharmacokinetics Written Summary 2013N179518_00 5. METABOLISM 9
10 m Pharmacokinetics Written Summary 2013N179518_00 6. EXCRETION 10
11 m Pharmacokinetics Written Summary 2013N179518_00 7. PHARMACOKINETIC DRUG INTERACTIONS The new drug interaction study with dolutegravir is listed in Table Dolutegravir: In Vitro Studies Mechanism based pharmacokinetic evaluation to predict the effect of dolutegravir on tenofovir kidney exposure A mechanistic kidney pharmacokinetic model, as part of the SimCYP population based PBPK (physiologically based pharmacokinetic) simulator, was used to assess the effect of kidney OAT1, OAT3 and MRP4 inhibition by dolutegravir on the kidney exposure of tenofovir in humans at the clinically efficacious dose of dolutegravir [Report 2013N171682]. A tabulated summary of this study is presented in m2.6.5, Table Following multiple once daily or twice daily dosing of 50 mg dolutegravir, no significant change in the renal clearance or proximal tubule concentration of tenofovir was predicted. These simulations suggest that dolutegravir is not likely to influence the kidney disposition of tenofovir via inhibition of OAT1, OAT3 or MRP4. 11
12 m Pharmacokinetics Written Summary 2013N179518_00 Table 7.1 List of New Pharmacokinetic Drug Interaction Studies Performed with Dolutegravir Type of Study Species (Strain)/ Test System No./Sex/ Group Method of Administration Dose (mg/kg/day) Duration of Dosing (Sampling Occasions) GLP Testing Facility Report No. (Study No.) Location in CTD Drug interactions - Computer modelling Key: QD = Once per day. BID = Twice per day. NA = Not applicable. Human NA In silico 50 QD & BID orally Multiple No GSK 2013N m Testing Facility: GSK = GlaxoSmithKline. 12
13 m Pharmacokinetics Written Summary 2013N179518_00 8. OTHER PHARMACOKINETIC STUDIES 13
14 m Pharmacokinetics Written Summary 2013N179518_00 9. DISCUSSION AND CONCLUSIONS TO PHARMACOKINETICS STUDIES No new previously unsubmitted pharmacokinetic studies have been conducted with abacavir or lamivudine. In vitro, dolutegravir did not inhibit human bile salt export pump (BSEP), but did inhibit multidrug resistance associated protein 4 (MRP4), organic cation transporter 1 and 3 (OAT1 and OAT3) and multidrug and toxin extrusion transporter1 and 2-K (MATE1 and MATE2-K). Following multiple once daily or twice daily dosing of 50 mg dolutegravir, no significant change in the renal clearance or proximal tubule concentration of tenofovir was predicted in a physiological based pharmacokinetic (PBPK) mechanistic kidney model. The information generated by these additional studies with dolutegravir and reported after the initial submission does not alter the original interpretation of the safe clinical use of dolutegravir in the treatment of patients with HIV and supports the use of dolutegravir in combination with abacavir and lamivudine in HIV patients when prescribed under the recommended therapeutic dosage regimen. 14
15 m Pharmacokinetics Written Summary 2013N179518_ REFERENCES Not applicable. 15
16 MODULE PHARMACOKINETICS TABULATED SUMMARY
17 m Pharmacokinetics Tabulated Summary TABLE OF CONTENTS PAGE 1. PHARMACOKINETICS: OVERVIEW OF PREVIOUSLY UNSUBMITTED STUDIES CONDUCTED WITH DOLUTEGRAVIR COMPLETED SINCE THE INITIAL NDA ANALYTICAL METHODS AND VALIDATION REPORTS PHARMACOKINETICS: ABSORPTION AFTER A SINGLE DOSE PHARMACOKINETICS: ABSORPTION AFTER REPEATED DOSE PHARMACOKINETICS: ORGAN DISTRIBUTION PHARMACOKINETICS: PLASMA PROTEIN BINDING PHARMACOKINETICS: STUDY IN PREGNANT OR NURSING ANIMALS PHARMACOKINETICS: OTHER DISTRIBUTION STUDIES PHARMACOKINETICS: METABOLISM IN VIVO PHARMACOKINETICS: METABOLISM IN VITRO PHARMACOKINETICS: POSSIBLE METABOLIC PATHWAYS PHARMACOKINETICS: INDUCTION/INHIBITION OF DRUG METABOLISING ENZYMES PHARMACOKINETICS: EXCRETION PHARMACOKINETICS: EXCRETION INTO BILE PHARMACOKINETICS: DRUG-DRUG INTERACTIONS PHARMACOKINETICS: OTHER
18 m Pharmacokinetics Tabulated Summary LIST OF TABLES PAGE Table 1.1 List of New Distribution Studies Performed with Dolutegravir...4 Table 1.2 Listing of New Pharmacokinetic Drug-Drug Interaction Studies Performed with Dolutegravir...5 Table 8.1 Dolutegravir: In Vitro Inhibition of Human Transporters...12 Table 15.1 Pharmacokinetics: Dolutegravir - Other Distribution Studies
19 m Pharmacokinetics Tabulated Summary 1. PHARMACOKINETICS: OVERVIEW OF PREVIOUSLY UNSUBMITTED STUDIES CONDUCTED WITH DOLUTEGRAVIR COMPLETED SINCE THE INITIAL NDA Table 1.1 List of New Distribution Studies Performed with Dolutegravir Type of Study Species (Strain)/ Test System No./Sex/ Group Method of Administration Form Dose (mg/kg/day) or Concentration Duration of Dosing (Sampling Occasions) GLP Testing Facility Report No. (Study No.) Location in CTD Inhibition of BSEP, OAT1, OAT3, MATE1, MATE2-K and MRP4 transport Human NA In vitro A 0.1 to 100 or 120 M NA No 2013N (XS-0406) m Key: A = GSK A, the sodium salt form. BSEP = Bile salt export pump. MATE = Multidrug and toxin extrusion. MRP = Multidrug resistance associated protein. NA = Not applicable. OAT = Organic anion transporter. Testing Facility: = 4
20 m Pharmacokinetics Tabulated Summary Table 1.2 Listing of New Pharmacokinetic Drug-Drug Interaction Studies Performed with Dolutegravir Type of Study Species (Strain)/ Test System No./Sex/ Group Method of Administration Dose (mg/kg/day) Duration of Dosing (Sampling Occasions) GLP Testing Facility Report No. (Study No.) Location in CTD Drug interactions - Computer modelling Key: QD = Once per day. BID = Twice per day. NA = Not applicable. Human NA In silico 50 QD & BID orally Multiple No GSK 2013N m Testing Facility: GSK = GlaxoSmithKline. 5
21 m Pharmacokinetics Tabulated Summary 2. ANALYTICAL METHODS AND VALIDATION REPORTS 6
22 m Pharmacokinetics Tabulated Summary 3. PHARMACOKINETICS: ABSORPTION AFTER A SINGLE DOSE 7
23 m Pharmacokinetics Tabulated Summary 4. PHARMACOKINETICS: ABSORPTION AFTER REPEATED DOSE 8
24 m Pharmacokinetics Tabulated Summary 5. PHARMACOKINETICS: ORGAN DISTRIBUTION 9
25 m Pharmacokinetics Tabulated Summary 6. PHARMACOKINETICS: PLASMA PROTEIN BINDING 10
26 m Pharmacokinetics Tabulated Summary 7. PHARMACOKINETICS: STUDY IN PREGNANT OR NURSING ANIMALS 11
27 m Pharmacokinetics Tabulated Summary 8. PHARMACOKINETICS: OTHER DISTRIBUTION STUDIES Table 8.1 Dolutegravir: In Vitro Inhibition of Human Transporters Test Article: Dolutegravir Target Inhibition IC50 ( M) Report No. Location in CTD BSEP None 2013N m MATE N m MATE2-K N m MRP N m OAT N m OAT N m Additional Information: BSEP = Bile salt export pump transporter; tested with membrane vesicles expressing BSEP. MATE = Multidrug and toxin extrusion transporter; tested with HEK293 cells expressing MATE1 or MATE2-K. MRP = Multidrug resistance associated protein. None = No inhibition detected. OATP = Organic anion transporting polypeptide. 12
28 m Pharmacokinetics Tabulated Summary 9. PHARMACOKINETICS: METABOLISM IN VIVO 13
29 m Pharmacokinetics Tabulated Summary 10. PHARMACOKINETICS: METABOLISM IN VITRO 14
30 m Pharmacokinetics Tabulated Summary 11. PHARMACOKINETICS: POSSIBLE METABOLIC PATHWAYS 15
31 m Pharmacokinetics Tabulated Summary 12. PHARMACOKINETICS: INDUCTION/INHIBITION OF DRUG METABOLISING ENZYMES 16
32 m Pharmacokinetics Tabulated Summary 13. PHARMACOKINETICS: EXCRETION 17
33 m Pharmacokinetics Tabulated Summary 14. PHARMACOKINETICS: EXCRETION INTO BILE 18
34 m Pharmacokinetics Tabulated Summary 15. PHARMACOKINETICS: DRUG-DRUG INTERACTIONS Table 15.1 Pharmacokinetics: Dolutegravir - Other Distribution Studies Test Article: Dolutegravir Type of Study: A mechanism based pharmacokinetic evaluation to predict the effect of GSK on tenofovir kidney exposure. Study System: Method: Report No.: 2013N Location in CTD: m Physiological based pharmacokinetic (PBPK) mechanistic kidney model (Simcyp v,12 R1) developed for steady state concentrations of tenofovir (300 mg once daily) predict that co-administration of DTG at 50 mg once daily would result in a minimal decrease in tenofovir renal clearance with no notable change in tenofovir exposure within the proximal tubule cells of the kidney. The mechanism behind the potential interaction between GSK and tenofovir does not impact the pharmacokinetics of GSK , as demonstrated in Study ING [Report RM2008/00793/00], the clinically observed GSK primary pharmacokinetic parameters (i.e., CL/F and Vd/F) were entered into SimCYP for the purposes of the simulation, with only small modifications as needed to simulate a GSK plasma concentration curve similar to that observed in Report RM2008/00793/00. Tenofovir pharmacokinetics and kidney disposition were simulated using a mechanistic kidney model implemented in the Simcyp ADME simulator (Version 12, Release 2, Simcyp Ltd, Sheffield, UK). Simulation and Sensitivity Analysis Results Following Co-Administration of 300 mg Tenofovir QD for 12 Days with 50 mg GSK QD or BID on Days 8 to mg Tenofovir QD x 12 Days with 50 mg GSK QD Days 8 to 12 Median of Proximal Tubule C max Values (ng/ml) 1 Predicted Fold Change Median Renal Clearance (L/hr) Tenofovir alone Tenofovir in the presence of GSK Fold change
35 m Pharmacokinetics Tabulated Summary Pharmacokinetics: Dolutegravir - Other Distribution Studies (Continued) 300 mg Tenofovir QD x 12 Days with 50 mg GSK QD Days 8 to 12 (10-Fold Reduced Tenofovir Diffusion Clearance in Proximal Tubule) Median of Proximal Tubule C max Values (ng/ml) 1 Predicted Fold Change Median Renal Clearance (L/hr) Tenofovir alone Tenofovir in the presence of GSK Fold change mg Tenofovir QD x 12 Days with 50 mg GSK QD Days 8 to 12 (10-Fold Increased GSK Kidney:Blood Ratio) Tenofovir alone Tenofovir in the presence of GSK Fold change mg Tenofovir QD x 12 Days with 50 mg GSK BID Days 8 to 12 Tenofovir alone Tenofovir in the presence of GSK Fold change
36 m Pharmacokinetics Tabulated Summary 16. PHARMACOKINETICS: OTHER 21
Prediction of the Effects of Renal Impairment on the Clearance for Organic Cation Drugs that. undergo Renal Secretion: A Simulation-Based Study
DMD Fast Forward. Published on February 28, 2018 as DOI: 10.1124/dmd.117.079558 This article has not been copyedited and formatted. The final version may differ from this version. Prediction of the Effects
More informationEvaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans
Supplement Article Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans The Journal of Clinical Pharmacology (2016), 56(S7) S82 S98 C 2016, The
More informationStrategy on Drug Transporter Investigation Why, How, Which & When. Jasminder Sahi
Strategy on Drug Transporter Investigation Why, How, Which & When Jasminder Sahi Intestine Drug Absorption PEPT1 OATPs MCTs AE2 Epithelial Cell MCTs MRP3 Liver Excretion via Liver Kidney MRPs OATPs N PT1
More informationTransporters DDI-2018
Transporters DDI-2018 Mark S. Warren, Ph.D. June 16, 2018 Senior Director of Assay Services DDI-2018: 21 st Conference on DDIs FDA guidance documents: A 21 year history 1997 2006 2012 2017 Each year, large
More informationStable transfected HEK293-OATP cells for transporter analysis A model system for the assay of drug uptake.
Stable transfected HEK293-OATP cells for transporter analysis A model system for the assay of drug uptake. PRIMACYT Cell Culture Technology GmbH, Hagenower Str. 73, D-19061 Schwerin, Germany E-mail: info@primacyt.com,
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplemental Materials
Supplemental Materials Evaluation of Ketoconazole and its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin and
More informationMODULE PHARMACOKINETICS WRITTEN SUMMARY
MODULE 2.6.4. PHARMACOKINETICS WRITTEN SUMMARY m2.6.4. Pharmacokinetics Written Summary TABLE OF CONTENTS PAGE 1. BRIEF SUMMARY...7 1.1. Test Substance...7 2. METHODS OF ANALYSIS...10 3. ABSORPTION...11
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationInvestigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin
Citation: CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 228 238; VC 2017 ASCPT All rights reserved doi:10.1002/psp4.12168 ORIGINAL ARTICLE Investigating Transporter-Mediated Drug-Drug Interactions Using
More informationWhat Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug
Title What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the U.S. FDA in 2015 Jingjing Yu, Zhu Zhou, Katie H. Owens, Tasha K. Ritchie,
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationWelcome to the webinar... We will begin shortly
Welcome to the webinar... We will begin shortly Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir,
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationMuhammad Fawad Rasool Feras Khalil Stephanie Läer
Clin Pharmacokinet (2015) 54:943 962 DOI 10.1007/s40262-015-0253-7 ORIGINAL RESEARCH ARTICLE A Physiologically Based Pharmacokinetic Drug Disease Model to Predict Carvedilol Exposure in Adult and Paediatric
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationPharmacological determinants of long-term treatment success
Professor David Back Liverpool, UK Pharmacological determinants of long-term treatment success Pharmacological Issues with Antiretroviral Therapy Intrinsic potency Bioavailability Effect of food and other
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationMonica Edholm Medica Medic l a Pr oducts Agency
EMA EFPIA workshop Break-out session no. 2 Case Study Title: M&S for dose adjustment in impaired patients M&S for dose adjustment in renally Monica Edholm MedicalProducts Agency Disclaimer: The views expressed
More informationDRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015
DRUG METABOLISM AND PHARMACOKINETICS (DMPK), H. Lundbeck A/S, LEGU@lundbeck.com November 2015 DMPK in Drug Discovery and Development Agenda Introduction Optimizing pharmacokinetic properties Absorption
More informationEVALUATION OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSIOLOGICALLY- BASED PHARMACOKINETIC MODEL
Drug metabolism and Pharmacokinetics/PK Sciences EVALUATIN F DRUG-DRUG INTERACTIN PTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSILGICALLY- BASED PHARMACKINETIC MDEL Imad Hanna,
More informationModule Summary of Clinical Pharmacology
Module 2.7.2 Summary of Clinical Pharmacology Copyright 2003 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 2 TABLE OF CONTENTS
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationT Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz
IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,
More informationAssessment of inhibitory effect of many therapeutically important drugs on bile acid transport by NTCP, BSEP and other transporters
ct 6, 26 Falk Symposium 155; XIX International Bile Acid Meeting Assessment of inhibitory effect of many therapeutically important drugs on bile acid transport by NTCP, BSEP and other transporters Kazuya
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationSummary of the risk management plan (RMP) for Viekirax (ombitasvir / paritaprevir / ritonavir)
EMA/775985/2014 Summary of the risk management plan (RMP) for Viekirax (ombitasvir / paritaprevir / ritonavir) This is a summary of the risk management plan (RMP) for Viekirax, which details the measures
More informationBasic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester
Basic Concepts in Pharmacokinetics Leon Aarons Manchester Pharmacy School University of Manchester Objectives 1. Define pharmacokinetics 2. Describe absorption 3. Describe distribution 4. Describe elimination
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationEffect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir
Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford
More informationComparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationPRODUCT MONOGRAPH. Dolutegravir (as dolutegravir sodium) 10, 25 and 50 mg tablets. Human immunodeficiency virus integrase strand transfer inhibitor
PRODUCT MONOGRAPH PrTIVICAY Dolutegravir (as dolutegravir sodium) 10, 25 and tablets Human immunodeficiency virus integrase strand transfer inhibitor ViiV Healthcare ULC 245, boulevard Armand-Frappier
More informationAntiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion
Slide 1 of 51 Antiretroviral Therapy Interactive Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health University of Alabama
More informationHEK293 cells transfected with human MATE1, MATE2-K, or vector control were established by
SUPPLEMENTAL DIGITAL CONTENT METHODS In Vitro Metformin Transport Studies Effect of Dolutegravir on Metformin Transport by MATE1 and MATE2-K HEK293 cells transfected with human MATE1, MATE2-K, or vector
More informationEvaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions. Bo Feng, Ph.D. DDI 2017 June 19-21, 2017
Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions Bo Feng, Ph.D. DDI 2017 June 19-21, 2017 Outline Background of renal transporters. Clinically observed transporter-mediated
More informationCryo Characterization Report (CCR)
Human Cryopreserved Hepatocytes Lot number: HUM4061B Date: October 19, 2014 Cryo Characterization Report (CCR) Lot Overview Qualification Catalog Number Quantity Cryopreserved human hepatocytes, Qualyst
More informationPRODUCT MONOGRAPH. Dolutegravir (as dolutegravir sodium) 10, 25 and 50 mg tablets. Human immunodeficiency virus integrase strand transfer inhibitor
PRODUCT MONOGRAPH PrTIVICAY Dolutegravir (as dolutegravir sodium) 10, 25 and tablets Human immunodeficiency virus integrase strand transfer inhibitor ViiV Healthcare ULC 245, boulevard Armand-Frappier
More informationExcretion of Drugs. Prof. Hanan Hagar Pharmacology Unit Medical College
Excretion of Drugs Prof. Hanan Hagar Pharmacology Unit Medical College Excretion of Drugs By the end of this lecture, students should be able to! Identify main and minor routes of excretion including renal
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TRIUMEQ dolutegravir, abacavir, and lamivudine tablets dolutegravir (as dolutegravir sodium), 600 mg abacavir (as abacavir sulfate) and 300
More informationSummary of the risk management plan (RMP) for Sirturo (bedaquiline)
EMA/16634/2014 Summary of the risk management plan (RMP) for Sirturo (bedaquiline) This is a summary of the risk management plan (RMP) for Sirturo, which details the measures to be taken in order to ensure
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TRIUMEQ dolutegravir, abacavir, and lamivudine tablets 50 mg dolutegravir (as dolutegravir sodium), 600 mg abacavir (as abacavir sulfate) and
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationComplexities of Hepatic Drug Transport: How Do We Sort It All Out?
Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Keith A. Hoffmaster Pfizer Research Technology Center Cambridge, MA NEDMDG 2005 Summer Symposium 06.08.2005 The Challenge Intestinal uptake
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPBPK modeling of renal impairment what is missing?
PBPK modeling of renal impairment what is missing? Aleksandra Galetin Centre for Applied Pharmacokinetic Research, University of Manchester, UK Outline of the presentation Physiological changes in renal
More informationInteraction of baicalin with transporters
Interaction of baicalin with transporters PhD thesis Kalaposné Kovács Bernadett Semmelweis University Doctoral School of Pharmaceutical Sciences Supervisor: External Consultant: Official reviewers: Dr.
More informationSelected Properties of Abacavir. Ziagen, ABC, 1592U89
Selected Properties of Abacavir Other names Manufacturer Pharmacology/Mechanism of Action Activity Resistance - genotypic Resistance - phenotypic Ziagen, ABC, 1592U89 Combination formulations: Trizivir
More informationCombination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects
Combination therapy with simeprevir and TMC647055/low dose ritonavir: dose anticipation using PBPK modeling and dose optimization in healthy subjects MC. Rouan, J. Snoeys, S. Ouwerkerk-Mahadevan, R. Verloes,
More informationIvy Song, 1 Kimberly Adkison, 2 Mark Lovern 3, Joannellyn Chiu 3, Jenny Huang 1, Cindy Vavro 1, Mounir Ait-Khaled 1, Brian Wynne 1 and Sherene Min 1
Pharmacokinetic-Pharmacodynamic Modeling & Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus Ivy Song, 1 Kimberly Adkison, 2 Mark Lovern
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationUsing virtual populations to solve drug development problems. Iain Gardner Head of Translational DMPK Science SIMCYP
Using virtual populations to solve drug development problems Iain Gardner Head of Translational DMPK Science SIMCYP Prediction of human PK (PD) in virtual individuals In vitro system In vitro CLu int Scaling
More informationNew issues in management of drug-drug interactions
New issues in management of drug-drug interactions Catia Marzolini Division of Infectious Diseases & Hospital Epidemiology www.hiv-druginteractions.org Presentation outline mechanisms of drug-drug interactions
More informationItraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com
More informationRenal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology
Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationSupplemental material to this article can be found at:
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/207/05/08/dmd.6.07458.dc 52-009X/45/7/755 764$25.00 https://doi.org/0.24/dmd.6.07458 DRUG METABOLISM AND
More informationEvaluation of Drug-Drug Interactions FDA Perspective
Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences
More informationPhysiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions s
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2017/08/31/dmd.117.076455.dc1 1521-009X/45/11/1156 1165$25.00 https://doi.org/10.1124/dmd.117.076455 DRUG
More informationThe Importance of Early Interaction with FDA: EOP2A Experiences
The Importance of Early Interaction with FDA: EOP2A Experiences Yaning Wang, Ph.D. Office of Clinical Pharmacology Center of Drug Evaluation and Research Food and Drug Administration Schematic of Development
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More information11/05/1431. Urine Formation by the Kidneys Tubular Processing of the Glomerular Filtrate
Urine Formation by the Kidneys Tubular Processing of the Glomerular Filtrate Chapter 27 pages 327 347 1 OBJECTIVES At the end of this lecture you should be able to describe: Absorptive Characteristics
More informationADME Review. Dr. Joe Ritter Associate Professor of Pharmacology
ADME Review Dr. Joe Ritter Associate Professor of Pharmacology 828-1022 jkritter@vcu.edu What percent of a weak base (pka = 7.5) and weak acid (pka = 3.5) will be respectively ionized in urine of ph 5.5?
More informationHIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract. Sandrine LEFEUVRE, Julie BOIS-MAUBLANC, Camélia GUBAVU,
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationPRODUCT MONOGRAPH. dolutegravir, abacavir, and lamivudine tablets
PRODUCT MONOGRAPH Pr TRIUMEQ dolutegravir, abacavir, and lamivudine tablets dolutegravir (as dolutegravir sodium), 600 mg abacavir (as abacavir sulfate) and 300 mg lamivudine Antiretroviral Agent ViiV
More informationBSEP inhibition and Drug Induced Liver Injury
BSEP inhibition and Drug Induced Liver Injury Gerry Kenna Pharmaceutical Director, Safer Medicines Trust www.safermedicines.org Drug Safety Consultant Overview Drug Induced Liver Injury (DILI) BSEP inhibition
More informationPresentation #: OP221
Pharmacokinetics, Safety and Tolerability of, a Novel Prodrug of Tenofovir, Administered as Ascending Multiple Doses to Healthy Volunteers and HBV-Infected Subjects Presentation #: OP22 Tawesak Tanwandee,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationIn vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction
SSX 3 rd Annual Conference (Oct 11, 2018) In vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction Yoshitane Nozaki, PhD DMPK Tsukuba Organic Anion Transporting Polypeptide (OATP)
More informationPHAR 7632 Chapter 16
PHAR 7632 Chapter 16 Routes of Excretion Routes of Excretion Student Objectives for this Chapter After completing the material in this chapter each student should:- be able to describe the various routes
More informationChallenges. Benefits. Control of viral load in plasma. Drug-drug interactions. Adverse effects/drug toxicities. Delay in HIV drug resistance
Benefits Challenges Control of viral load in plasma Drug-drug interactions Delay in HIV drug resistance Longer life expectancy Adverse effects/drug toxicities Drug resistant HIV strains Raltegravir Structural/pharmacokinetic/pharmacodynamic
More informationName: UFID: PHA Exam 2. Spring 2013
PHA 5128 Exam 2 Spring 2013 1 Carbamazepine (5 points) 2 Theophylline (10 points) 3 Gentamicin (10 points) 4 Drug-drug interaction (5 points) 5 Lidocaine (5 points) 6 Cyclosporine (5 points) 7 Phenobarbital
More informationRedefining The Math. The less the better WEEKS. Daclatasvir 60 mg Tablet K S
Redefining The Math 12 24 WEEKS W EE K S Hepatitis C; the most notorious of all hepatitis infections, has becoming a world threat due to its high morbidity and mortality rate. Moreover, with the prevalence
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationTRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA
TRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3tc 300 mg were used. Bioequivalence has been demonstrated. DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine
More informationPharmacokinetic Modeling & Simulation in Discovery and non-clinical Development
Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development Where do we stand? Disclaimer I am not a bioinformatician, mathematician or biomedical engineer. I am a simple minded pharmacist,
More informationWHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION
PHARMACOKINETICS I Absorption & Distribution LEARNING OUTCOMES By the end of the lecture students will be able to.. Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/08/21) Define pharmacokinetics,
More informationEffects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program
Effects of Renal Disease on Pharmacokinetics October 8, 2015 Juan J. L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program `Office of Clinical Research Training and Medical Education National
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationEffect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
More informationDefine the terms biopharmaceutics and bioavailability.
Pharmaceutics Reading Notes Define the terms biopharmaceutics and bioavailability. Biopharmaceutics: the area of study concerning the relationship between the physical, chemical, and biological sciences
More information